Related Experiment Videos
Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis
T J Stillwell1, R C Benson, R A DeRemee
1Department of Urology, Mayo Clinic, Rochester, Minnesota.
Arthritis and Rheumatism
|April 1, 1988
Summary
Cyclophosphamide therapy for Wegener's granulomatosis can cause hemorrhagic cystitis in 15% of patients. Long-term monitoring is crucial for detecting bladder cancer and other complications.
Area of Science:
- Urology
- Oncology
- Rheumatology
Background:
- Wegener's granulomatosis is a systemic vasculitis.
- Cyclophosphamide is a common treatment for Wegener's granulomatosis.
- Cyclophosphamide is known to cause urotoxicity.
Purpose of the Study:
- To investigate the incidence of hemorrhagic cystitis in patients with Wegener's granulomatosis treated with cyclophosphamide.
- To identify risk factors for cyclophosphamide-induced urotoxicity.
- To emphasize the importance of long-term follow-up for bladder complications.
Main Methods:
- Retrospective analysis of 111 patients with Wegener's granulomatosis.
- Patients received cyclophosphamide therapy.
- Diagnosis of hemorrhagic cystitis based on gross hematuria or cystoscopy.
Main Results:
- Hemorrhagic cystitis developed in 17% of patients.
- 3 patients developed bladder carcinoma.
- 52% experienced new microhematuria.
- Higher cyclophosphamide dose and duration correlated with urotoxicity.
Conclusions:
- Cyclophosphamide therapy is associated with significant urotoxicity, including hemorrhagic cystitis and bladder cancer.
- Long-term surveillance is essential for patients treated with cyclophosphamide.
- Development of protective therapies against cyclophosphamide-induced urotoxicity is ongoing.